Investment Thesis :
- Holds a leading positions in Australia, France and Scandinavia.
- Earnings will begin to rise in FY22-24 as a result of pent-up demand on waiting lists.
- Has a well-diversified portfolio with a large scale.
- Australia’s largest private hospital operator, with strong industry fundamentals
- Favourable macro-industry trends include an ageing and growing population, the spread of chronic disease, and more innovation, treatment, and technology, all of which are driving demand to private hospital.
- Supportive government policy (tax incentive for people to get private health insurance).
- Ongoing brownfield program driving earnings and offshore earnings growth
- Significant international operation paves way for the firm to grow internationally in near future.
- Attractive industry dynamics with high entry barriers for new firms.
Key Risks:
- Competitive risk (new hospitals, new beds), from listed and unlisted hospital operators
- Brownfield projects fail to deliver the earnings uplift.
- Cost pressures (negotiating price increases with private health insurance companies).
- Government policy on private health insurance is changing.
- Execution risk (able to get the uplift in earnings from brownfield projects).
- Snap economic lockdowns due to Covid-19
- Currency risk
Key financial highlights of year2021:
In relative to the previous corresponding period i.e pcp (herein pcp is year 2020)
- During the year 2021, RHC revenue increased by 3.9% to $12.4bn.
- The increase in revenue was driven by strong earning growth across all of its geographical segments-i.e from Asia Pacific, UK and Europe.
- In Asia Pacific, revenue from patients increased by 7.8% to $5.4bn reflecting strong growth in surgical admission (2) In U.K, revenue increased by 10.2% to $1,024.1m and included payments from the NHSE of $417.6m representing net cost recovery for services provided by Ramsay to the NHSE during the year (3) Europe revenue increased by 6.9% to $6,839.9m and included government grants of $428.3m and was impacted by 80m euros from the sale of a portfolio of nine German hospitals in 1H21
- EBIT increased by 29.1% to $1.1bn and statutory profit increased by 58.1% to $449m, reflecting a strong increase in admissions.
- The Board declared a fully franked final dividend of 103cps, bringing the FY21 dividend to 151.5cps (up by 142.4 %) and representing a payout ratio of 79 percent of statutory profit.
- During the underlying period ROCE improved by 60bps to 9.3% and ROIC gained by 260bps to 7%.
- Operating cash flow fell by 11.9 % to $1.5 billion, owing to changes in working capital as a result of cash loans from the French government while FCF fell by 14.8 percent to $85,
- Financial metrics improved, with net debt (excluding lease liabilities) fallen by 15 % to $2.4 billion, lowering leverage to 3.7 times from 4.4 times.
Company Profile:
Ramsay Health Care Ltd (RHC) is a company that provides medical services. RHC has hospitals, day surgery centres, treatment facilities, rehabilitation centres, and psychiatric units all around the world. It has about 500 sites throughout Australia, the United Kingdom, France, Sweden, Norway, Denmark, Germany, Indonesia, Malaysia, Hong Kong, Italy, and the Nordic countries.
General Advice Warning
Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.